Dave Jain, DO
Internal Medicine · Kennett, MONPI 1265540777
Payments from drug & device makers
Across 340 payments — averaging $13.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$1K
- Amgen$691
- Novo Nordisk$655
- Johnson & Johnson$451
- AstraZeneca$349
- Amarin Pharma, Inc.$237
- plus $1K from 24 others
What the payments were for
- Speaking & faculty fees$140%
- Food & beverage$4,62398%
- Education$912%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 71 | $1,140 |
| Amgen | 53 | $691 |
| Novo Nordisk | 49 | $655 |
| Johnson & Johnson | 43 | $451 |
| AstraZeneca | 20 | $349 |
| Amarin Pharma, Inc. | 20 | $237 |
| Lilly USA, LLC | 11 | $175 |
| GSK | 10 | $132 |
| Pfizer | 6 | $130 |
| E.r. Squibb & Sons, L.L.C. | 9 | $122 |
| Sanofi-aventis U.S. LLC | 10 | $116 |
| Sunovion Pharmaceuticals Inc. | 10 | $107 |
| Grifols USA, LLC | 6 | $92 |
| Otsuka America Pharmaceutical, Inc. | 3 | $63 |
| Bayer | 3 | $49 |
| Astellas Pharma US Inc | 2 | $24 |
| AbbVie | 1 | $19 |
| Novartis | 1 | $16 |
| Alkermes, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Acorda Therapeutics, Inc | 1 | $14 |
| Ascensia Diabetes Care US Inc. | 1 | $14 |
| Gilead | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Merck | 1 | $13 |
| Abbott | 1 | $12 |
| Eisai Inc. | 1 | $12 |
| Sumitomo Pharma America, Inc. | 1 | $11 |
How this compares
$4,728 in reported general payments places this provider in the 85th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 199 | $167,993 |
| EliquisApixaban | 124 | $81,061 |
| TradjentaLinagliptin | 96 | $64,385 |
| XareltoRivaroxaban | 91 | $57,931 |
| Repatha SureclickEvolocumab | 52 | $28,718 |
| MyrbetriqMirabegron | 39 | $21,157 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $18,524 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $17,778 |
| VascepaIcosapent Ethyl | 39 | $15,566 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 14 | $14,908 |
| EntrestoSacubitril/Valsartan | 21 | $14,491 |
| OzempicSemaglutide | 14 | $13,969 |
| MounjaroTirzepatide | 12 | $13,069 |
| TrulicityDulaglutide | 12 | $11,485 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $8,439 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $1,140 | $232,378295 claims |
| PfizerEliquis | $130 | $81,061124 claims |
| Johnson & JohnsonXarelto | $451 | $57,93191 claims |
| Lilly USA, LLCMounjaro, Trulicity | $175 | $24,55324 claims |
| Astellas Pharma US IncMyrbetriq | $24 | $21,15739 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $116 | $18,07526 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $132 | $17,88736 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $349 | $16,03753 claims |
| NovartisEntresto | $16 | $14,49121 claims |
| Novo NordiskOzempic | $655 | $13,96914 claims |
| MerckJanuvia | $13 | $8,27513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Kennett
- Timothy SmithSaint Peters$21.4M
- Craig DietzKansas City$4M
- Michael ReschakSaint Louis$3.1M
- Dima DandachiColumbia$1.2M
- Santosh SharmaKansas City$782K
- Jianbo WangChesterfield$643K
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Dubert GuerreroIndependence$369K
- Hany SalamaSaint Louis$279K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.